Four of the five trials are nearing completion - should Novartis move any of these trials to a phase 2b/3 then this would be significant validation of Lag-3.
By association, Immutep's in-house trial programs with Merck (and Pfizer) could add significant value to Immutep's current market cap.
May also open up other doors for new non-dilutive capital, example - "Pfizer Breakthrough Growth Initiative will invest up to $500 million across a portfolio of clinical-stage biotechnology companies"
Four of the five trials are nearing completion - should Novartis...
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
46.0¢ |
Change
-0.025(5.15%) |
Mkt cap ! $552.8M | |||
| Open | High | Low | Value | Volume |
| 46.0¢ | 47.0¢ | 45.5¢ | $399.6K | 868.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 545395 | 46.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 46.5¢ | 71398 | 15 |
View Market Depth
| Last trade - 12.01pm 08/05/2024 (20 minute delay) ? |
|
|||||
|
Last
46.3¢ |
Change
-0.025 ( 3.67 %) |
||||
| Open | High | Low | Volume | ||
| 47.5¢ | 47.5¢ | 45.8¢ | 351713 | ||
| Last updated 11.55am 08/05/2024 ? | |||||
| IMM (ASX) Chart |